Enovis price target raised to $70 from $67 at Baird

Baird analyst Jeffrey Johnson raised the firm’s price target on Enovis to $70 from $67 and keeps an Outperform rating on the shares. The firm said they believe some investors are growing increasingly worried orthopedic backlogs have already depleted but theye think that’s dead wrong and they would be buying the weakness.